MANDARA Mepolizumab v benralizumab for EGPA BEN is non-inferior Secondary outcomes- less eosinophils and more pts completely off GCs Now approved for EGPA Year in Review #ACR24 Pillinger @RheumNow https://t.co/ThLziABvzu

• https://x.com/ericdeinmd/status/1857773289474507223/photo/1

Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

• https://x.com/Dr_Brian_MD/status/1857502436371607960/photo/1

RA pearls from #ACR24 review course: 1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi. 2. Multimorbidity=Poor outcomes, High risk for mortality. 3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg

• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1
• https://x.com/AdelaCastro222/status/1857575812788040158/photo/1

Risk for atypical femoral fracture: 🚨Asian race - 4-6x higher risk Duration of use is greater risk than older age Higher risk when given for osteoporosis than cancer treatment - Compare: osteonecrosis of jaw more common with cancer Rx #ACR24 Review Course @RheumNow https://t.co/V8cD5QWNGp

• https://x.com/ericdeinmd/status/1857473638892441852/photo/1